Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Cancer Research Horizons is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme. Diamond Light Source accelerates electrons to near light speed, producing bright light that is directed into research instruments known as beamlines. Cancer Research Horizons and its drug discovery site… Read More
This paid-for advertorial by SCIEX appeared in DDW Volume 24 – Issue 2, Spring 2023 Imagine having the ability to consistently identify metabolic soft spots from an experiment that uses liquid chromatography coupled to mass spectrometry (LC-MS), reducing the need for additional safety testing in the drug discovery phase. Metabolite identification A… Read More
Astex Pharmaceuticals and The Medicines Discovery Institute, Cardiff University (MDI) have agreed a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases. The collaboration brings together the research expertise of Dr Emyr Lloyd-Evans and Dr Helen Waller-Evans in lysosomal biology, the drug discovery… Read More
Don’t miss your chance to register for the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Attendees will learn:… Read More
Fragment-based drug discovery (FBDD) is one strategy used to identify novel and potent lead compounds. Don’t miss out on this free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragments are small molecules with a low molecular weight (less than… Read More
Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process. Watch the webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Key Learning Objectives: How FBDD can help identify novel and potent lead… Read More
Watch the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process. Fragments are small molecules… Read More
Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process. Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec, is now available to watch online. … Read More
Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process. Watch this free event, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragments are… Read More
